

Minutes of the Institute Biosafety Committee Meeting

April 15, 2026

Convened at: 1:00 pm and Adjourned at 2:38 pm

Present: Drs. Thanavala (Co-Chair), Ding, Fang, Ionov, McGray, Gerber, Mr. Hartley, Ms. Holtz, Ms Keough and Mr. Flagler.

Absent: Dr. Gelman, Mr. Atwal, Mr. Caruana, Ms. Herter

ORSP Staff: Ms Pusateri, Ms. Bennett

Guests: None

Meeting Place: Virtual meeting/Teams.

Minutes of March 11, 2026 were approved.

Vote: Unanimous.

Adverse Event/Accident/Incident Report

February and March Employee Health Service reports; no follow up required.

ORSP - No reports.

Old Business

1. Safety Story; this months story highlighted watching for accidental needle sticks.
2. Laboratory inspections; February and March are pending:
Laboratories were visited February 5th with Dr. Thanavala joining the team.
 - a. Evans BSL 2 lab: OES to follow up (see checklist).
 - b. Repasky BSL2 lab: OES to follow up (see checklist).
 - c. Webster BSL2+ lab: OES to follow up (see checklist).Laboratories were visited March 5th with Dr. Ionov joining the team.
 - a. Barbi BSL 2+ lab: OES to follow up (see checklist).
 - b. Goodrich BSL2 lab: OES to follow up (see checklist).
 - c. Wilde BSL2+ lab: OES to follow up (see checklist).

New Business:

1. Lab educational visits: April biosafety inspections were cancelled.
The next inspection date will be Thursday May 7th with Dr. McGray joining the team.

Protocol review:

16 Biosafety applications were reviewed, 7 were continuing reviews.

3 Protocols referenced Virus

Application for Benchwork 25-12-1713: Approved Pending.

Reviewed by Dr. Thanavala

The Initial application for lab, 25-12-1713 entitled: "Identification of Etiology of Febrile Illness from Postmortem Samples from Northern Tanzania." PI: Bonnewell, John was approved pending designated member review of a revised application.

The purpose of this protocol is to store post-mortem blood and tissue samples collected in Tanzania from deceased patients with febrile illness of unknown etiology. The samples will not be studied at Roswell Park.

Biosafety agents include: Potential presence of tropical infectious pathogens in the stored samples

Application for 1358M, 1365M, 1391M, 1556M, Lab: Approved Pending.

Reviewed by Dr. McGray

The Initial application for 1358M, 1365M, 1391M, 1556M, lab, 26-01-1716 entitled: “The Dasgupta Lab Biosafety Protocol.” PI: Dasgupta, Subhamoy was approved pending designated member review of a revised application.

The purpose of this protocol is threefold 1) to investigate the metabolic pathways that facilitate the castration resistant prostate cancer cells to grow inside the bone 2) how the metabolic enzyme, PFKFB4, functions as a key driver of breast cancer metastasis and how targeting this enzyme could help prevent metastasis and 3) role of a cellular group of proteins called tri-carboxylic acid (TCA) cycle enzymes as novel tumor regulators in glioblastoma.

Biosafety agents include: Replication deficient lentivirus and replication deficient adenovirus.

Note: Quorum was maintained during review/approval

Application for 1341M/Lab Based: Approved.

Reviewed by Dr. Ionov

The amendment for 1341M/lab based application, 26-03-1728 entitled: “Role of Tumor Suppressor Genes in Development and Cancer.” PI: Goodrich, David was approved.

The purpose of this protocol is to use human cell lines and patient derived organoids derived from deidentified tissue as well as mouse cell lines and organoids from genetically engineered mice.

Biosafety agents include: replication defective viruses (adenovirus, lentivirus, retrovirus).

1 Protocol referenced Bacteria

Application for 1720M/Lab Based: Approved.

Reviewed by Dr. Thanavala

The amendment for 1720M/lab based application, 26-01-1719 entitled: “A Listeria-Based Immunogen to Study Antigen-Specific T Cell Responses In Vivo.” PI: Longo, Joseph was approved.

The purpose of this protocol is to use attenuated strain of the bacterium *Listeria monocytogenes* that has been engineered to express the model antigen ovalbumin and use it to study antigen-specific T cell responses in vivo.

Biosafety agents include: attenuated strain of the bacterium *Listeria monocytogenes*

Exempt from full committee review: none

Amendments:

Application for Lab: Full Committee review; Approved Pending.

Reviewed by Dr. Ding

The amendment to Lab based 25-05-1670 entitled: “Activating Anti-MDS Immunity Through Restoration of the Immune Microenvironment” PI: Nemeth, Michael was approved pending designated member review of revised application.

The purpose of this protocol is to generate mouse myeloid progenitor cell lines with MDS-associated mutation

Biosafety agents used include: Use of retroviral constructs expressing a HOXB8-ER and DNMT3A-R882H.

Application for Lab/1395M: Approved

Reviewed by Dr. Gelman

The amendment for 1395M protocol 24-07-1608 entitled: “Qiang Li Biosafety Application” PI: Li, Qiang was approved 3/20/2026.

Biosafety agents include: new cell lines for 1395M, new lentiviral agent/insert.

Application for Lab/1683M: Approved

Reviewed by Dr. Gelman

The amendment for 1683M protocol 24-08-1619 entitled: "Evaluation of Cell Therapies for Cancer and Immune Related Disorders" PI: Davila, Marco was approved 3/20/2026.

Biosafety agents include: modified murine cell lines

Application for Lab/1461M: Approved

Reviewed by Dr. Gelman

The amendment for 1461M protocol 25-07-1681 entitled: "Genetic Targeting of T Lymphocytes to Cancer Antigens for Use in Adoptive Cell Therapy" PI: Brentjens, Renier was approved 4/1/2026.

Biosafety agents include: new cell lines and CAR T cells.

Application for Lab: Approved


Reviewed by Dr. Gelman

The amendment for lab based protocol 24-08-1619 entitled: "Evaluation of Cell Therapies for Cancer and Immune Related Disorders" PI: Davila, Marco was approved 4/3/2026.

Biosafety agents include: additional human cells.

See attached for complete list.

Respectfully Submitted,

A handwritten signature in black ink that reads "Yasmin Thanavala." The signature is written in a cursive style with a horizontal line above and below the name.

Yasmin Thanavala, PhD
Institute Biosafety Committee Co-Chair
Professor of Oncology, Immunology